Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Current Assets for 6 consecutive years, with $240.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 43.33% year-over-year to $240.3 million, compared with a TTM value of $240.3 million through Dec 2025, up 43.33%, and an annual FY2025 reading of $240.3 million, up 43.33% over the prior year.
  • Current Assets was $240.3 million for Q4 2025 at Xeris Biopharma Holdings, up from $224.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $240.3 million in Q4 2025 and bottomed at $124.4 million in Q3 2021.
  • Average Current Assets over 5 years is $170.3 million, with a median of $164.5 million recorded in 2023.
  • The sharpest move saw Current Assets decreased 16.35% in 2023, then surged 43.33% in 2025.
  • Year by year, Current Assets stood at $142.6 million in 2021, then surged by 31.01% to $186.8 million in 2022, then dropped by 16.35% to $156.3 million in 2023, then rose by 7.29% to $167.7 million in 2024, then soared by 43.33% to $240.3 million in 2025.
  • Business Quant data shows Current Assets for XERS at $240.3 million in Q4 2025, $224.0 million in Q3 2025, and $185.6 million in Q2 2025.